Pharma BD Deal Intelligence
Daiichi Sankyo / Plexxikon: Partially Achieved (Score: 59/100)
Full analysis, sources & comparables →Daiichi Sankyo nabs tiny Plexxikon in $935M deal to accelerate oncology pipeline and gain proprietary scaffold-based drug discovery platform
Daiichi Sankyo shuttering Plexxikon R&D site in San Francisco as company pivots strategic focus toward antibody-drug conjugate therapies
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Daiichi Sankyo acquired Plexxikon for $805M + $130M milestones for melanoma drug vemurafenib.
Daiichi Sankyo / Plexxikon: Partially Achieved (Score: 59/100)
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Daiichi Sankyo Company, Limited / Plexxikon Inc. (this deal) | 2011 | $935M | 51 |
| Daiichi Sankyo Company, Limited / Ambit Biosciences | 2006 | $410M | 62 |
| Daiichi Sankyo Company, Limited / Zepharma Inc. | 2006 | $200M | 57 |
| Daiichi Sankyo Company, Limited / Ranbaxy Laboratories Limited | 2008 | $4.6B | 14 |
| Daiichi Sankyo Company, Limited / Nosis Biosciences, Inc. | 2025 | — | — |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
← Browse all deals · How we score deals
More: 2011 deals · Daiichi Sankyo Company, Limited deals · Oncology deals